JP2014065708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014065708A5 JP2014065708A5 JP2013192736A JP2013192736A JP2014065708A5 JP 2014065708 A5 JP2014065708 A5 JP 2014065708A5 JP 2013192736 A JP2013192736 A JP 2013192736A JP 2013192736 A JP2013192736 A JP 2013192736A JP 2014065708 A5 JP2014065708 A5 JP 2014065708A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- ala
- replace
- acid substitution
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 51
- 238000006467 substitution reaction Methods 0.000 claims 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims 46
- 230000027455 binding Effects 0.000 claims 31
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 238000000034 method Methods 0.000 claims 11
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 11
- 230000007935 neutral effect Effects 0.000 claims 9
- 230000002378 acidificating effect Effects 0.000 claims 7
- -1 Leu Chemical group 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013192736A JP5913243B2 (ja) | 2010-03-30 | 2013-09-18 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010079667 | 2010-03-30 | ||
| JP2010079667 | 2010-03-30 | ||
| JP2010250830 | 2010-11-09 | ||
| JP2010250830 | 2010-11-09 | ||
| JP2013192736A JP5913243B2 (ja) | 2010-03-30 | 2013-09-18 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535527A Division JP5415624B2 (ja) | 2010-03-30 | 2011-03-30 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032586A Division JP6029252B2 (ja) | 2010-03-30 | 2016-02-24 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014065708A JP2014065708A (ja) | 2014-04-17 |
| JP2014065708A5 true JP2014065708A5 (enExample) | 2014-05-29 |
| JP5913243B2 JP5913243B2 (ja) | 2016-04-27 |
Family
ID=44260244
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535527A Active JP5415624B2 (ja) | 2010-03-30 | 2011-03-30 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2013192736A Active JP5913243B2 (ja) | 2010-03-30 | 2013-09-18 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2016032586A Active JP6029252B2 (ja) | 2010-03-30 | 2016-02-24 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2016203205A Active JP6518222B2 (ja) | 2010-03-30 | 2016-10-17 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2019079713A Active JP6850317B2 (ja) | 2010-03-30 | 2019-04-19 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2021034982A Active JP7186813B2 (ja) | 2010-03-30 | 2021-03-05 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2022190445A Pending JP2023022203A (ja) | 2010-03-30 | 2022-11-29 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2025022184A Pending JP2025081443A (ja) | 2010-03-30 | 2025-02-14 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535527A Active JP5415624B2 (ja) | 2010-03-30 | 2011-03-30 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032586A Active JP6029252B2 (ja) | 2010-03-30 | 2016-02-24 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2016203205A Active JP6518222B2 (ja) | 2010-03-30 | 2016-10-17 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2019079713A Active JP6850317B2 (ja) | 2010-03-30 | 2019-04-19 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2021034982A Active JP7186813B2 (ja) | 2010-03-30 | 2021-03-05 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2022190445A Pending JP2023022203A (ja) | 2010-03-30 | 2022-11-29 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
| JP2025022184A Pending JP2025081443A (ja) | 2010-03-30 | 2025-02-14 | 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20130131319A1 (enExample) |
| EP (4) | EP3181581B1 (enExample) |
| JP (8) | JP5415624B2 (enExample) |
| KR (6) | KR101831464B1 (enExample) |
| CN (2) | CN102918057B (enExample) |
| AU (1) | AU2011233390B2 (enExample) |
| BR (1) | BR112012024710B1 (enExample) |
| CA (1) | CA2794860C (enExample) |
| DK (1) | DK2552955T3 (enExample) |
| ES (3) | ES2995193T3 (enExample) |
| HR (3) | HRP20171080T1 (enExample) |
| HU (3) | HUE069214T2 (enExample) |
| LT (1) | LT2552955T (enExample) |
| MX (1) | MX2012011338A (enExample) |
| PL (3) | PL3181581T3 (enExample) |
| PT (2) | PT3181581T (enExample) |
| RU (1) | RU2745989C9 (enExample) |
| SG (2) | SG10201703798YA (enExample) |
| SI (2) | SI2552955T1 (enExample) |
| TW (2) | TWI667257B (enExample) |
| WO (1) | WO2011122011A2 (enExample) |
Families Citing this family (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| BR112013021526B1 (pt) | 2011-02-25 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio |
| WO2012133782A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| TW201726745A (zh) * | 2011-09-30 | 2017-08-01 | 中外製藥股份有限公司 | 促進抗原消失的抗原結合分子 |
| WO2013047748A1 (ja) * | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| BR112014007484A2 (pt) | 2011-09-30 | 2017-04-04 | Chugai Pharmaceutical Co Ltd | molécula de ligação a antígeno de indução de resposta imune a antígeno alvo |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| CA2857159C (en) | 2011-11-30 | 2024-05-07 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| EP2813568B1 (en) | 2012-02-09 | 2025-04-23 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| RU2624128C2 (ru) | 2012-02-15 | 2017-06-30 | Ф. Хоффманн-Ля Рош Аг | Аффинная хроматография с применением fc-рецепторов |
| KR20250007041A (ko) | 2012-02-24 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자 |
| NZ712508A (en) | 2012-03-16 | 2018-06-29 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| RS57414B1 (sr) * | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih |
| AU2013204581B2 (en) | 2012-03-16 | 2015-06-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| KR20200037434A (ko) | 2012-04-27 | 2020-04-08 | 바이오아트라, 엘엘씨 | 수정된 항체 영역 및 그의 용도 |
| KR20150016579A (ko) | 2012-05-30 | 2015-02-12 | 추가이 세이야쿠 가부시키가이샤 | 표적 조직 특이적 항원 결합 분자 |
| ES2856272T3 (es) * | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| EP2889377B1 (en) | 2012-08-24 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Fcyriib-specific fc region variant |
| WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| GB201302878D0 (en) * | 2013-02-19 | 2013-04-03 | Argen X Bv | Modified igG molecules |
| EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| KR102266819B1 (ko) | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN105765063B (zh) | 2013-09-30 | 2021-05-07 | 中外制药株式会社 | 应用改变的辅助噬菌体制备抗原结合分子的方法 |
| KR20250075744A (ko) | 2013-11-11 | 2025-05-28 | 추가이 세이야쿠 가부시키가이샤 | 개변된 항체 가변영역을 포함하는 항원 결합 분자 |
| CN111304752B (zh) | 2013-12-04 | 2024-12-31 | 中外制药株式会社 | 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库 |
| JP6778110B2 (ja) | 2014-01-15 | 2020-10-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改善されたプロテインＡ結合を有するＦｃ領域バリアント |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| CN106103478B (zh) | 2014-03-21 | 2020-04-03 | 豪夫迈·罗氏有限公司 | 抗体体内半寿期的体外预测 |
| US20170267780A1 (en) * | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| RU2714153C2 (ru) * | 2014-06-12 | 2020-02-12 | Ф. Хоффманн-Ля Рош Аг | СПОСОБ ОТБОРА АНТИТЕЛ С МОДИФИЦИРОВАННЫМ ВЗАИМОДЕЙСТВИЕМ С FcRn |
| FR3024453B1 (fr) * | 2014-08-01 | 2018-06-29 | Lab Francais Du Fractionnement | Procede de production de variants ayant un fc presentant une sialylation amelioree |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| JP6576456B2 (ja) * | 2014-11-06 | 2019-09-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種 |
| US10307480B2 (en) * | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| KR20170078677A (ko) * | 2014-11-06 | 2017-07-07 | 에프. 호프만-라 로슈 아게 | Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법 |
| TWI880146B (zh) | 2014-11-11 | 2025-04-11 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| RS62749B1 (sr) | 2014-12-19 | 2022-01-31 | Chugai Pharmaceutical Co Ltd | Anti-c5 antitela i načini njihove upotrebe |
| CN113956354A (zh) | 2015-01-22 | 2022-01-21 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CA2974547A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof |
| JP6130983B2 (ja) | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| IL285375B2 (en) | 2015-09-18 | 2025-11-01 | Chugai Pharmaceutical Co Ltd | Il-8-binding antibodies and uses thereof |
| JP6142069B1 (ja) | 2015-12-18 | 2017-06-07 | 中外製薬株式会社 | 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN109071645A (zh) | 2016-01-08 | 2018-12-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| EP3463461A4 (en) | 2016-05-27 | 2020-05-20 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| CN116041514A (zh) | 2016-06-06 | 2023-05-02 | 希望之城 | Baff-r抗体及其用途 |
| JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｃ５抗体及びそれらの使用 |
| EP3472200A4 (en) | 2016-06-17 | 2020-04-01 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF |
| CN118388638A (zh) * | 2016-08-02 | 2024-07-26 | 威特拉公司 | 工程化多肽及其应用 |
| IL264626B (en) | 2016-08-05 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Composition for prophylaxis or treatment of il-8 related diseases |
| EP3497120A1 (en) * | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| HUE061656T2 (hu) | 2017-01-06 | 2023-07-28 | Scholar Rock Inc | Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával |
| EP3569615A4 (en) * | 2017-01-13 | 2020-07-29 | Hanx Biopharmaceutics, Inc | PROCESS FOR IMPROVING THE BINDING AFFINITY OF AN IGG ANTIBODY TOWARDS FCRN AND PROLONGING THE SERIC HALF-LIFE OF THE latter |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE |
| KR101949891B1 (ko) | 2017-01-31 | 2019-02-19 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| UA128814C2 (uk) * | 2017-02-10 | 2024-10-30 | Генмаб Б.В. | Поліпептид та його застосування |
| IL307373A (en) | 2017-02-17 | 2023-11-01 | Denali Therapeutics Inc | Polypeptides that bind to a transgenic transferrin receptor |
| EP4342541A3 (en) * | 2017-04-07 | 2024-07-03 | Kookmin University Industry Academy Cooperation Foundation | Antibody fc variants for increased blood half-life |
| KR20190141659A (ko) | 2017-04-21 | 2019-12-24 | 스태튼 바이오테크놀로지 비.브이. | 항-apoc3 항체 및 이의 사용 방법 |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| JP7710827B2 (ja) * | 2017-06-05 | 2025-07-22 | ヤンセン バイオテツク，インコーポレーテツド | 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質 |
| EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
| EP3658184B1 (en) | 2017-07-27 | 2023-09-06 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| JP7191087B2 (ja) | 2017-08-11 | 2022-12-16 | リサーチ ディベロップメント ファウンデーション | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
| CN111315213B (zh) | 2017-10-06 | 2023-09-12 | 普罗塞纳生物科学有限公司 | 抗甲状腺素运载蛋白抗体 |
| PE20210042A1 (es) | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | Metodos para detectar transtiretina |
| US12235261B2 (en) | 2017-10-20 | 2025-02-25 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring cellular uptake of molecules |
| US12128101B2 (en) | 2017-10-26 | 2024-10-29 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| MX2020004512A (es) | 2017-10-31 | 2020-08-13 | Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos. | |
| JP7731196B2 (ja) | 2017-11-14 | 2025-08-29 | 中外製薬株式会社 | 抗Ｃ１ｓ抗体および使用方法 |
| EA202091130A1 (ru) | 2017-11-29 | 2020-08-28 | Протена Биосайенсис Лимитед | Лиофилизованный препарат моноклонального антитела к транстиретину |
| TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| CN111630065A (zh) | 2017-12-13 | 2020-09-04 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
| AU2019214865B2 (en) * | 2018-02-02 | 2025-04-10 | OncoC4, Inc. | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| WO2019152413A1 (en) * | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| TWI827585B (zh) | 2018-03-15 | 2024-01-01 | 日商中外製藥股份有限公司 | 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法 |
| CN112105260B (zh) * | 2018-03-26 | 2023-04-28 | 瑞泽恩制药公司 | 用于测试治疗剂的人源化啮齿动物 |
| EP3773718A4 (en) | 2018-04-06 | 2022-01-19 | aTyr Pharma, Inc. | COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES |
| CA3094312A1 (en) * | 2018-04-13 | 2019-10-17 | Chugai Seiyaku Kabushiki Kaisha | Anti-complement component antibodies and methods of use |
| WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| CN112105645A (zh) | 2018-04-18 | 2020-12-18 | Xencor股份有限公司 | Il-15/il-15ra异二聚体fc融合蛋白及其用途 |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
| CA3099554A1 (en) | 2018-05-14 | 2019-11-21 | Oncoimmune, Inc. | Anti-cd24 compositions and uses thereof |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| GB201809341D0 (en) | 2018-06-07 | 2018-07-25 | Ucb Biopharma Sprl | Multi-domain proteins with increased native state colloidal stability |
| CA3105000A1 (en) | 2018-06-26 | 2020-01-02 | Kyowa Kirin Co., Ltd. | Antibody binding to cell adhesion molecule 3 |
| JP7397444B2 (ja) | 2018-06-26 | 2023-12-13 | 協和キリン株式会社 | コンドロイチン硫酸プロテオグリカン－５に結合する抗体 |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SG11202100221VA (en) | 2018-07-19 | 2021-02-25 | Regeneron Pharma | Chimeric antigen receptors with bcma specificity and uses thereof |
| DE112019003835T5 (de) | 2018-08-01 | 2021-05-27 | Chugai Seiyaku Kabushiki Kaisha | Arzneimittel zur verwendung bei der behandlung oder vorbeugung einer mit c5 in zusammenhang stehenden erkrankung sowie verfahren zur behandlung oder vorbeugung einer mit c5 in zusammenhang stehenden erkrankung |
| WO2020032230A1 (ja) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | 抗ｃｄ１３７抗原結合分子およびその使用 |
| MX2021004059A (es) | 2018-10-12 | 2021-09-23 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. |
| CN119405797A (zh) | 2018-10-30 | 2025-02-11 | 亚力兄制药公司 | 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用 |
| PE20211867A1 (es) * | 2018-11-01 | 2021-09-21 | Shandong New Time Pharmaceutical Co Ltd | Anticuerpos biespecificos y su uso |
| WO2020132646A1 (en) | 2018-12-20 | 2020-06-25 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| JP2022514290A (ja) | 2018-12-20 | 2022-02-10 | ジェネンテック， インコーポレイテッド | 改変抗体ｆｃおよび使用方法 |
| JP7601758B2 (ja) | 2019-03-19 | 2024-12-17 | 中外製薬株式会社 | Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ |
| WO2020209318A1 (ja) | 2019-04-10 | 2020-10-15 | 中外製薬株式会社 | Ｆｃ領域改変抗体の精製方法 |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| KR20220004087A (ko) * | 2019-04-19 | 2022-01-11 | 추가이 세이야쿠 가부시키가이샤 | 항체 개변 부위 인식 키메라 수용체 |
| US12473353B2 (en) | 2019-05-15 | 2025-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule, a pharmaceutical composition, and a method |
| WO2020247827A1 (en) * | 2019-06-06 | 2020-12-10 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| EP3980130A1 (en) * | 2019-06-06 | 2022-04-13 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| AU2020289477A1 (en) * | 2019-06-07 | 2022-02-03 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| US20220288219A1 (en) * | 2019-07-08 | 2022-09-15 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| CA3149199A1 (en) * | 2019-07-30 | 2021-02-04 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| AU2020330307A1 (en) * | 2019-08-12 | 2022-03-17 | CSL Innovation Pty Ltd | Complement C2 binding proteins and uses thereof |
| WO2021067761A1 (en) | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| EP4037775A1 (en) * | 2019-10-04 | 2022-08-10 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| US20220396618A1 (en) * | 2019-10-31 | 2022-12-15 | The Research Foundation For The State University Of Newyork | Rage antibodies, fragments and uses thereof |
| BR112022012010A2 (pt) | 2019-12-18 | 2022-08-30 | Hoffmann La Roche | Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune |
| US20230058982A1 (en) | 2019-12-27 | 2023-02-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody and use thereof |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2021154046A1 (ko) * | 2020-01-29 | 2021-08-05 | 고려대학교 산학협력단 | pH-감응성 FC 변이체 |
| TWI895351B (zh) | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| EP4133269A1 (en) * | 2020-04-08 | 2023-02-15 | F. Hoffmann-La Roche AG | Large molecule unspecific clearance assay |
| US20230416371A1 (en) | 2020-08-28 | 2023-12-28 | Chugai Seiyaku Kabushiki Kaisha | Heterodimer fc polypeptide |
| EP4277931A1 (en) | 2021-01-13 | 2023-11-22 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| US20240141065A1 (en) * | 2021-02-03 | 2024-05-02 | Mythic Therapeutics, Inc. | Anti-met antibodies and uses thereof |
| CN117500829A (zh) | 2021-06-18 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| BR112023022992A2 (pt) | 2021-06-25 | 2024-01-23 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-ctla-4 |
| EP4361176A4 (en) | 2021-06-25 | 2025-03-12 | Chugai Seiyaku Kabushiki Kaisha | USE OF ANTI-CTLA-4 ANTIBODIES |
| CN115572331A (zh) * | 2021-07-06 | 2023-01-06 | 联邦生物科技(珠海横琴)有限公司 | 一种具有增强FcRn受体结合的突变子 |
| EP4387994A4 (en) * | 2021-08-20 | 2025-07-02 | Univ New York State Res Found | IGA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION |
| US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| KR20250164749A (ko) * | 2023-03-24 | 2025-11-25 | 파라곤 테라퓨틱스, 인크. | Fcrn에 결합하는 fc 단편 및 사용 방법 |
| US12286475B2 (en) | 2023-07-31 | 2025-04-29 | Sanofi | Anti-GPRC5D antibodies and compositions |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| CN120365429B (zh) * | 2025-06-30 | 2025-09-05 | 上海交通大学医学院附属仁济医院 | Cd70特异性纳米抗体、分子影像探针及其制备方法和应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPS63149900A (ja) | 1986-12-15 | 1988-06-22 | Toshiba Corp | 半導体メモリ |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
| EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| CA2177988A1 (en) | 1993-12-03 | 1995-06-08 | Kazuo Higuchi | Expression vector for preparing an anti-body-variable-region library |
| AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| BR9713294A (pt) | 1996-09-26 | 2000-10-17 | Chugai Pharmaceutical Co Ltd | "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano" |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| NZ539776A (en) * | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2442801A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with gntiii |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| WO2004058821A2 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| EP1697415A1 (en) * | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| DE102004032634A1 (de) | 2004-07-06 | 2006-02-16 | Sms Demag Ag | Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk |
| CA2573192C (en) | 2004-08-04 | 2013-09-10 | Applied Molecular Evolution Inc. | Variant fc regions |
| EP1778728A2 (en) * | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006067847A1 (ja) | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
| WO2006073941A2 (en) | 2004-12-31 | 2006-07-13 | Genentech, Inc. | Polypeptides that bind br3 and uses thereof |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| DK2021463T3 (en) | 2006-05-19 | 2017-01-16 | Alder Biopharmaceuticals Inc | Culture method to obtain a cloned population of antigen-specific B cells |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| CA2703997C (en) | 2007-12-26 | 2017-04-04 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| CN101932593B (zh) * | 2008-01-29 | 2014-08-20 | 埃博灵克斯股份有限公司 | 稳定蛋白和多肽的方法 |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| US20110081347A1 (en) | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| JP5028372B2 (ja) | 2008-09-26 | 2012-09-19 | 京セラドキュメントソリューションズ株式会社 | 画像処理装置、画像処理方法及び画像処理プログラム |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| AU2009303526B2 (en) * | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CA2700030C (en) | 2009-04-16 | 2019-11-05 | Accenture Global Services Gmbh | Touchpoint customization system |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| CN105218674A (zh) * | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| CN106459192B (zh) | 2014-06-30 | 2021-08-03 | 默克专利股份公司 | 具有pH依赖性抗原结合的抗TNFa抗体 |
-
2011
- 2011-03-28 TW TW105129449A patent/TWI667257B/zh active
- 2011-03-28 TW TW100110549A patent/TWI667346B/zh active
- 2011-03-30 WO PCT/JP2011/001888 patent/WO2011122011A2/en not_active Ceased
- 2011-03-30 KR KR1020127028433A patent/KR101831464B1/ko active Active
- 2011-03-30 CA CA2794860A patent/CA2794860C/en active Active
- 2011-03-30 KR KR1020187004382A patent/KR101974794B1/ko active Active
- 2011-03-30 PL PL17154576.7T patent/PL3181581T3/pl unknown
- 2011-03-30 ES ES20160156T patent/ES2995193T3/es active Active
- 2011-03-30 KR KR1020227039559A patent/KR20220157513A/ko not_active Ceased
- 2011-03-30 JP JP2012535527A patent/JP5415624B2/ja active Active
- 2011-03-30 HU HUE17154576A patent/HUE069214T2/hu unknown
- 2011-03-30 SG SG10201703798YA patent/SG10201703798YA/en unknown
- 2011-03-30 SG SG2012069670A patent/SG184163A1/en unknown
- 2011-03-30 SI SI201131227T patent/SI2552955T1/sl unknown
- 2011-03-30 KR KR1020197011803A patent/KR102269707B1/ko active Active
- 2011-03-30 PL PL20160156.4T patent/PL3702368T3/pl unknown
- 2011-03-30 PL PL11714860T patent/PL2552955T3/pl unknown
- 2011-03-30 CN CN201180026699.3A patent/CN102918057B/zh active Active
- 2011-03-30 PT PT171545767T patent/PT3181581T/pt unknown
- 2011-03-30 DK DK11714860.1T patent/DK2552955T3/en active
- 2011-03-30 BR BR112012024710-7A patent/BR112012024710B1/pt active IP Right Grant
- 2011-03-30 HR HRP20171080TT patent/HRP20171080T1/hr unknown
- 2011-03-30 EP EP17154576.7A patent/EP3181581B1/en active Active
- 2011-03-30 ES ES11714860.1T patent/ES2633597T3/es active Active
- 2011-03-30 SI SI201132118T patent/SI3181581T1/sl unknown
- 2011-03-30 EP EP24198835.1A patent/EP4501956A3/en active Pending
- 2011-03-30 HU HUE11714860A patent/HUE033812T2/en unknown
- 2011-03-30 MX MX2012011338A patent/MX2012011338A/es active IP Right Grant
- 2011-03-30 HU HUE20160156A patent/HUE069966T2/hu unknown
- 2011-03-30 US US13/637,415 patent/US20130131319A1/en not_active Abandoned
- 2011-03-30 HR HRP20241623TT patent/HRP20241623T1/hr unknown
- 2011-03-30 HR HRP20241779TT patent/HRP20241779T1/hr unknown
- 2011-03-30 KR KR1020247018157A patent/KR20240094003A/ko not_active Ceased
- 2011-03-30 AU AU2011233390A patent/AU2011233390B2/en active Active
- 2011-03-30 KR KR1020217019076A patent/KR102468436B1/ko active Active
- 2011-03-30 ES ES17154576T patent/ES2989715T3/es active Active
- 2011-03-30 CN CN202110596518.6A patent/CN113307868A/zh active Pending
- 2011-03-30 EP EP20160156.4A patent/EP3702368B1/en active Active
- 2011-03-30 EP EP11714860.1A patent/EP2552955B1/en not_active Revoked
- 2011-03-30 LT LTEP11714860.1T patent/LT2552955T/lt unknown
- 2011-03-30 RU RU2012146098A patent/RU2745989C9/ru active
- 2011-03-30 PT PT117148601T patent/PT2552955T/pt unknown
-
2013
- 2013-09-18 JP JP2013192736A patent/JP5913243B2/ja active Active
-
2016
- 2016-02-22 US US15/050,145 patent/US20160244526A1/en not_active Abandoned
- 2016-02-24 JP JP2016032586A patent/JP6029252B2/ja active Active
- 2016-07-14 US US15/210,360 patent/US20170002080A1/en not_active Abandoned
- 2016-07-14 US US15/210,353 patent/US20170002066A1/en not_active Abandoned
- 2016-10-17 JP JP2016203205A patent/JP6518222B2/ja active Active
-
2017
- 2017-04-24 US US15/495,026 patent/US20170226206A1/en not_active Abandoned
-
2019
- 2019-04-19 JP JP2019079713A patent/JP6850317B2/ja active Active
-
2021
- 2021-03-05 JP JP2021034982A patent/JP7186813B2/ja active Active
-
2022
- 2022-11-03 US US18/052,258 patent/US20230220083A1/en active Pending
- 2022-11-29 JP JP2022190445A patent/JP2023022203A/ja active Pending
-
2025
- 2025-02-14 JP JP2025022184A patent/JP2025081443A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014065708A5 (enExample) | ||
| IL299282A (en) | Enhanced variable complexes of immunoglobulins | |
| JP2014528906A5 (enExample) | ||
| ES2978309T3 (es) | Métodos para purificar anticuerpos | |
| CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
| RU2021134101A (ru) | Модифицированная j-цепь | |
| PE20131465A1 (es) | Moleculas de union a 4-1 bb | |
| CA2953714C (en) | Anti-tnfa antibodies with ph-dependent antigen binding | |
| JP2016500250A5 (enExample) | ||
| JP2015529236A5 (enExample) | ||
| HK1252827A1 (zh) | 结合lag-3的分子和其使用方法 | |
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
| JP2014158485A5 (enExample) | ||
| WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
| CR20180311A (es) | Aglutinantes de tnf mejorados | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| JP2018502572A5 (enExample) | ||
| EA201790438A1 (ru) | Антигенсвязывающие белки, которые связываются с cxcr5 | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| JP2017529097A5 (enExample) | ||
| FI2953971T3 (fi) | Il-11r-sitojaproteiineja ja niiden käyttöjä | |
| EA201691779A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| JP2012514997A5 (enExample) | ||
| EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения |